Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TL-102
- Development stage
- Preclinical
- Lead developer
- Spirovant Sciences
- Modality
- Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Inhalation
01
Overview
TL-102 is a lentiviral-based gene therapy product candidate developed by Talee Bio (now Spirovant Sciences) for the treatment of cystic fibrosis. It is designed as a mutation-agnostic therapy to accelerate the development of treatments for all cystic fibrosis patients, particularly those with limited or no other treatment options, by overcoming historical challenges in gene therapy delivery to the lung. The therapy is intended to address the underlying cause of the disease.
Beyond the preview
Go deeper on TL-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TL-102.